Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Immutep ( (IMMP) ) just unveiled an announcement.
On November 3, 2025, Immutep Limited announced it received a €2,588,954 (~ A$4,567,769) R&D tax incentive from the French Government under the Crédit d’Impôt Recherche scheme. This incentive supports the company’s research and development activities conducted in Europe during the 2024 calendar year. The funds will be used to further the global clinical development of eftilagimod alfa and IMP761, enhancing Immutep’s position in the immunotherapy sector.
The most recent analyst rating on (IMMP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. However, positive technical indicators provide some optimism, suggesting potential short-term bullish momentum. The valuation remains unattractive due to negative earnings and the absence of dividends.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), which can stimulate or suppress the immune response. Immutep aims to provide innovative treatment options for patients and maximize shareholder value.
Average Trading Volume: 125,410
Technical Sentiment Signal: Sell
Current Market Cap: $269.1M
See more data about IMMP stock on TipRanks’ Stock Analysis page.